Sanofi, Regeneron score win against Amgen patents on PCSK9 med Repatha

Sanofi and Regeneron have been battling with PCSK9 rival Amgen over patents for their cholesterol drugs for years, with Amgen at one point securing an injunction against sales of the partners’ Praluent. Now, Sanofi and Regeneron have persuaded a judge that certain claims of two Amgen patents covering PCSK9 med Repatha are invalid.